TABLE 1.
The baseline characteristics of the study group and the control group
| Variables | Study group (n = 26) | Control group (n = 26) | P value |
|---|---|---|---|
| Age, years | 61.88 ± 10.46 | 66.85 ± 10.21 | .060 |
| Female gender | 9 (34.6%) | 3 (11.5%) | .048 |
| DM | 12 (46.2%) | 12 (46.2%) | 1.000 |
| Hypertension | 26 (100.0%) | 26 (100.0%) | 1.000 |
| Hyperlipidemia | 17 (65.4%) | 17 (65.4%) | 1.000 |
| Current smoking | 2 (7.7%) | 7 (26.9%) | .140 |
| ACEIs/ARB use | 23 (83.5%) | 21 (80.8%) | .703 |
| Stain use | 17 (65.4%) | 18 (69.2%) | .768 |
| Old stroke | 0 (0.0%) | 2 (7.7%) | .490 |
| Old MI | 6 (23.1%) | 9 (34.6%) | .358 |
| History of CAD | 16 (64.0%) | 11 (44.0%) | .156 |
| History of PCI | No: 23 (92.0%) | No: 15 (68.2%) | .063 |
| Stage of CKD |
CKD3: 20 (76.9%) CKD4: 6 (23.1%) |
CKD3: 20 (76.9%) CKD4: 6 (23.1%) |
1.000 |
| Body height, cm | 160.27 ± 7.56 | 164.10 ± 6.14 | .053 |
| Body weight, kg | 68.05 ± 11.92 | 71.07 ± 13.47 | .396 |
| Body mass index | 26.40 ± 3.70 | 26.69 ± 5.21 | .821 |
| Creatinine level, g/dL | 2.00 ± 0.80 | 2.00 ± 0.69 | .647 |
| BUN, g/dL | 27.50 ± 6.56 | 33.58 ± 16.86 | .096 |
| CCr, cc/min | 38.99 ± 12.70 | 39.23 ± 12.27 | .944 |
| Ratio of uTP to uCre, mg/g | 933.9 ± 1464.7 | 1316.5 ± 2086.0 | .956 |
| Ratio of uAL to uCre, mg/g | 548.5 ± 879.9 | 690.9 ± 1093.1 | .701 |
Note: Study group = group 1; control group = group 2.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; BUN, blood urea nitrogen; CAD, coronary artery disease; Ccr, creatinine clearance rate; CKD, chronic kidney disease; DM, diabetes mellitus; MI, myocardial infarction; uAL, urine albumin; uCre, urine creatinine; uTP, urine total protein.